Everest Medicines Acquires Exclusive Rights to VIS-101
Everest Medicines has acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for serious eye disorders, in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
Collaboration Details
The license was acquired from Visara, Inc., a subsidiary of NovaBridge Biosciences, listed on the Nasdaq Global Market under the symbol "NBP".
- Upfront payment: US$7 million (approximately RMB49.7 million)
- Reimbursement for prior expenses: up to RMB24.0 million
- Potential future payments: up to US$89 million
This collaboration marks Everest's strategic expansion into ophthalmology, a high-potential therapeutic area.
Author's summary: Everest Medicines expands into ophthalmology with VIS-101 license.
More News
- “You don’t sell new highs”: Ben Griffiths on why this rally still has room to run
- Residents plead for reassessment pause at Lackawanna County budget hearing
- Zach Cregger’s Weapons is a Wildly Brilliant Rollercoaster and One of the Year’s Best Films -
- Billie Eilish Calls on Billionaires to Do More for People in Need
- The Casandra Cascade: Industrialisation Of Fear - FNArena.com
- Metal Object in Roadway on Highway 101 North at Mile Marker 37.50 Leads to Traffic Hazard
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism